---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-130934"
form_type: "8-K"
ticker: "VCEL"
cik: "0000887359"
company_name: "Vericel Corp"
filed_at: "2022-12-29T23:59:59+00:00"
generated_at: "2026-06-20T22:13:17.020344+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Vericel gets FDA approval for NexoBrid to treat severe thermal burns in adults

## Summary
- FDA approved NexoBrid (anacaulase-bcdb) for eschar removal in adults with deep partial- and full-thickness thermal burns.
- Approval based on Phase 3 DETECT study meeting primary endpoint of complete eschar removal vs placebo.
- NexoBrid showed shorter time to eschar removal and lower incidence of surgical removal vs standard of care.
- Commercial launch expected in Q2 2023; company plans to establish it as new standard of care.
- Expands Vericel's target addressable market beyond sports medicine into severe burn care.

## SEC filing metadata
- accession: 0001104659-22-130934
- form_type: 8-K
- ticker: VCEL
- cik: 0000887359
- company_name: Vericel Corp
- filed_at: 2022-12-29T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/887359/000110465922130934/0001104659-22-130934-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/887359/000110465922130934/tm2233709d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-130934
- JSON: https://secwatch.observer/filing/0001104659-22-130934.json
- Plain text: https://secwatch.observer/filing/0001104659-22-130934.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.